Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success
In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical studies have shown potential for increasing muscular mass and ameliorating the pathological features of dystrophic...
Main Authors: | Tue L. Nielsen, John Vissing, Thomas O. Krag |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/3/533 |
Similar Items
-
Identification of ligand-selective peptidic ActRIIB-antagonists using phage display technology
by: Kotaro Sakamoto, et al.
Published: (2017-09-01) -
BMP3 suppresses colon tumorigenesis via ActRIIB/SMAD2-dependent and TAK1/JNK signaling pathways
by: Jialing Wen, et al.
Published: (2019-10-01) -
Activin A levels are raised during human tuberculosis and blockade of the activin signaling axis influences murine responses to M. tuberculosis infection
by: Natalie E. Nieuwenhuizen, et al.
Published: (2024-03-01) -
Molecular characteristic of activin receptor IIB and its functions in growth and nutrient regulation in Eriocheir sinensis
by: Jingan Wang, et al.
Published: (2020-09-01) -
Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease
by: Pradeep Harish, et al.
Published: (2020-03-01)